Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Teleflex Inc. (TFX) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Medical Instruments & Supplies
$126.49
+1.23 (0.98%)10 Quality Stocks Worth Considering Now
Researching Teleflex (TFX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TFX and similar high-potential opportunities.
Based on our analysis of 25 Wall Street analysts, TFX has a neutral consensus with a median price target of $145.00 (ranging from $135.00 to $200.00). The overall analyst rating is Buy (6.1/10). Currently trading at $126.49, the median forecast implies a 14.6% upside. This outlook is supported by 2 Buy, 11 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Richard Newitter at Truist Securities, projecting a 58.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for TFX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
May 5, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $137.00 |
May 5, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $173.00 |
May 2, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $137.00 |
May 2, 2025 | RBC Capital | Shagun Singh | Sector Perform | Maintains | $145.00 |
Apr 11, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $140.00 |
Apr 2, 2025 | Citizens Capital Markets | David Turkaly | Market Perform | Reiterates | $0.00 |
Mar 12, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Mar 5, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $191.00 |
Mar 4, 2025 | B of A Securities | Craig Bijou | Underperform | Downgrade | $140.00 |
Mar 3, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $149.00 |
Feb 28, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $146.00 |
Feb 28, 2025 | Piper Sandler | Matt O'Brien | Neutral | Downgrade | $140.00 |
Dec 18, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $200.00 |
Dec 16, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Nov 4, 2024 | Truist Securities | Richard Newitter | Hold | Reiterates | $227.00 |
Nov 1, 2024 | Mizuho | Anthony Petrone | Neutral | Maintains | $250.00 |
Nov 1, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $245.00 |
Nov 1, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Oct 14, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $255.00 |
Oct 8, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $275.00 |
The following stocks are similar to Teleflex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Teleflex Inc. has a market capitalization of $5.54B with a P/E ratio of 38.8x. The company generates $3.01B in trailing twelve-month revenue with a 5.0% profit margin.
Revenue growth is -5.0% quarter-over-quarter, while maintaining an operating margin of +19.0% and return on equity of +3.5%.
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Provides specialized medical devices for healthcare.
Teleflex Inc. generates revenue by developing, manufacturing, and supplying a wide array of medical devices for healthcare providers. Their products cater to various specialties including anesthesia, cardiology, and urology, with a focus on enhancing patient outcomes through innovation in minimally invasive surgical procedures and critical care applications.
Founded in 1943 and headquartered in Wayne, Pennsylvania, Teleflex Inc. is a significant player in the healthcare equipment industry, committed to addressing healthcare challenges and advancing medical technology solutions globally. The company's extensive market reach and specialized expertise position it well for continued growth in the health technology sector.
Healthcare
Medical Instruments & Supplies
14,500
Mr. Liam J. Kelly
United States
1988
Teleflex Incorporated (NYSE: TFX) will pay a quarterly cash dividend of $0.34 per share on June 16, 2025, to shareholders of record by May 20, 2025.
Teleflex's dividend declaration signals financial stability and commitment to returning value to shareholders, potentially attracting income-focused investors and boosting stock demand.
Rosen Law Firm is investigating potential securities claims against Teleflex Incorporated (NYSE: TFX) for allegedly misleading business information. Affected shareholders may seek compensation with no upfront costs.
Allegations of misleading information can lead to legal claims against Teleflex, potentially impacting stock value and investor confidence. Compensation opportunities may arise for affected shareholders.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors who purchased Teleflex Incorporated (NYSE: TFX). Interested parties can visit bgandg.com/TFX for more information.
The investigation into Teleflex could indicate potential legal issues, affecting investor confidence and stock performance, which may lead to volatility in Teleflex's share price.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for purchasers of Teleflex Incorporated (NYSE: TFX). Affected investors can find more information at bgandg.com/TFX.
The investigation into Teleflex could indicate potential legal or financial issues, impacting stock performance and investor confidence in the company.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Teleflex Incorporated (NYSE: TFX) investors. Purchasers of Teleflex securities can find more info at bgandg.com/TFX.
The investigation into Teleflex may indicate potential legal issues or financial irregularities, potentially affecting stock performance and investor sentiment.
Use of the Titan SGSโข Stapler shows lower postoperative reflux rates and shorter hospital stays compared to multi-fire staplers, with no impact on total weight loss at one year.
Enhanced surgical outcomes and reduced hospital stays with the Titan SGSโข Stapler can lead to cost savings and improved patient satisfaction, positively impacting healthcare investments and market competitiveness.
Based on our analysis of 25 Wall Street analysts, Teleflex Inc. (TFX) has a median price target of $145.00. The highest price target is $200.00 and the lowest is $135.00.
According to current analyst ratings, TFX has 2 Buy ratings, 11 Hold ratings, and 1 Sell ratings. The stock is currently trading at $126.49. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict TFX stock could reach $145.00 in the next 12 months. This represents a 14.6% increase from the current price of $126.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
Teleflex Inc. generates revenue by developing, manufacturing, and supplying a wide array of medical devices for healthcare providers. Their products cater to various specialties including anesthesia, cardiology, and urology, with a focus on enhancing patient outcomes through innovation in minimally invasive surgical procedures and critical care applications.
The highest price target for TFX is $200.00 from Richard Newitter at Truist Securities, which represents a 58.1% increase from the current price of $126.49.
The lowest price target for TFX is $135.00 from at , which represents a 6.7% increase from the current price of $126.49.
The overall analyst consensus for TFX is neutral. Out of 25 Wall Street analysts, 2 rate it as Buy, 11 as Hold, and 1 as Sell, with a median price target of $145.00.
Stock price projections, including those for Teleflex Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.